title: [Effect of protein C activator on overall haemostasis potential in donor and hip arthroplasty patient plasma].
abstract: A method of overall haemostasis potential (OHP) determination for quantitative and rapid estimation of coagulation-fibrinolysis balance in plasma has been presented. The method is based on the analysis of the absorbance at 350 nm vs. time curve, which records the clot formation and dissolution in plasma in the presence of thromboplastin and t-PA. Three parameters of coagulation system--time, rate of formation and maximal turbidity of the clot, and three parameters of fibrinolytic system--half-, full-time and maximal rate of the clot dissolution, and main integral parameter--the area under the curve that characterizes the size and time of the clot existence and expresses OHP of plasma, can be determined by this method. It was shown that OHP value of patients plasma was 3.8 times more than that of the donor plasma. It is in concordance with elevated level of Fg (4.25 mg/ml), soluble fibrin (50 microg/ml), D dimer (630 ng/ml) and insufficient decrease of APC activity (93%) in patients. AcPC, added to donor and patient plasma, reduced OHP value 1.6 and 3.7 times, correspondingly. AcPC increased amidase activity of thrombin and APC in the donor plasma, and did not change that of plasmin. These data indicated that the effect of AcPC on OHP is mediated by formation ofAPC that helps to reduce the level of inhibitors in the investigated plasma.
authors.forename: A M
authors.initials: AM
authors.lastname: Rublenko
authors.forename: L P
authors.initials: LP
authors.lastname: Urvant
authors.forename: Ie M
authors.initials: IeM
authors.lastname: Makogonenko
authors.forename: T M
authors.initials: TM
authors.lastname: Platonova
authors.forename: P Iu
authors.initials: PIu
authors.lastname: Tsap
authors.forename: T M
authors.initials: TM
authors.lastname: Chernyshenko
authors.forename: I M
authors.initials: IM
authors.lastname: Kolesnikova
authors.forename: V O
authors.initials: VO
authors.lastname: Fishchenko
authors.forename: E V
authors.initials: EV
authors.lastname: Lugovs'koĭ
mesh_terms: D019540:Area Under Curve; D019644:Arthroplasty, Replacement, Hip; D001780:Blood Coagulation Tests; D005337:Fibrin / Q000378:metabolism; D005341:Fibrinolysin / Q000378:metabolism; D005342:Fibrinolysis / Q000187:drug effects*; D005343:Fibrinolytic Agents / Q000378:metabolism; D006439:Hemodynamics; D006615:Hip / Q000503:physiopathology / Q000601:surgery; D006801:Humans; D007118:Immunoassay; D009842:Oligopeptides / Q000494:pharmacology; D010958:Plasminogen / Q000378:metabolism; D011486:Protein C / Q000378:metabolism*; D013053:Spectrophotometry; D013917:Thrombin / Q000378:metabolism*; D013925:Thromboplastin / Q000494:pharmacology; D013927:Thrombosis / Q000097:blood*; D010959:Tissue Plasminogen Activator / Q000097:blood
chemical_list: D005343:Fibrinolytic Agents; D009842:Oligopeptides; D011486:Protein C; C047135:protein C activator peptide; D005337:Fibrin; D010958:Plasminogen; D013925:Thromboplastin; D013917:Thrombin; D010959:Tissue Plasminogen Activator; D005341:Fibrinolysin